Final results of a randomised trial comparing 'Tomudex'® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer

Annals of Oncology

Volumn 7, Issue 9, 1996, Pages 961-965

  Cunningham, D ^a   Zalcberg, J R ^b   Rath, U ^c   Oliver, I ^d   Van Cutsem, E ^e   Svensson, C ^f   Seitz, J F ^g   Harper, P ^g   Kerr, D ^h   Perez Manga, G ⁱ  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b HEIDELBERG REPATRIATION HOSPITAL   (Australia)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f STOCKHOLM SÖDER HOSPITAL   (Sweden)

^g GUY S HOSPITAL   (United Kingdom)

^h QUEEN ELIZABETH HOSPITAL   (United Kingdom)

ⁱ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

'Tomudex'; Chemotherapy; Colorectal cancer; Palliation; Thymidylate synthase inhibitor

Indexed keywords

FLUOROURACIL; FOLINIC ACID; RALTITREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUINAZOLINES; THIOPHENES;

EID: 5544237608     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010800     Document Type: Article

References (11)

1. Cunningham D, Zalcberg JR, Rath U et al. 'Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Can 1995; 31A; 1945-54.
2. Elliot R. Analysis of drug costs for the management of chemotherapy related side effects in advanced colorectal cancer. J Oncol Clin Pharm 1996; 2:186-90.
3. Hayward JL, Carbone PP, Henson JC et al. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977; 13:89-94.
4. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6:65-70.
5. Jackman AL, Taylor GA, Gibson W et al. ICI D1694, quinazoine antifolate thymidylate synthetase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res 1991; 51: 5579-86.
6. Lipsitz S, Kim K, Zhao L. Analysis of repeated categorical data using generalised estimating equations. Stat Med 1994; 13 1149-63.
7. Ross P., Heron J, Cunningham D. Cost of treating advanced colorectal cancer: A retrospective comparison of treatment regimens. Eur J Cancer 1996; 32(A)(Suppl): S13-S17.
8. Wittes RE (ed). Manual of Oncologic Therapeutics. Philadelphia: JB Lipincott 1989/1990.
9. World Health Organization (WHO). WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO Offset Publications, No. 48, 1979.
10. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organisation for research and treatment of cancer QLQ-C30: A quality of life instrument for use in International Clinical Trials in Oncology. J Natl Cancer Inst 1993; 85: 365-76.
11. Zalcberg JR, Cunningham D, Van Cutsem E et al. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996; 14:716-21.